Prolonged intertreatment interval improves outcomes to EGFR rechallenge in metastatic colorectal cancer
Randomised trials and real-world data propel the anti-EGFR rechallenge approach towards standard of care, but more solid evidence is needed
ctDNA and RNA-based tests are expanding colorectal cancer screening options
The availability of simpler, less-invasive methodologies may help to encourage participation in secondary prevention programmes
Atezolizumab and bevacizumab after transarterial chemoembolisation prolongs progression-free survival in unresectable hepatocellular carcinoma
Data from the TALENTACE trial add to growing evidence supporting the combination of immunotherapy plus anti-VEGF component with TACE
Quality of Life data in immune oncology trials: from side note to centre stage?
Despite greater attention being given to treatment effects on patient wellbeing, the high heterogeneity of methodologies still limits the usefulness of QoL assessment
Decoding genomic and transcriptomic signatures in colorectal cancer – next steps?
Newer technologies build on current knowledge to provide greater insights in the molecular landscape
Combinations show promise in hepatocellular carcinoma populations with poor prognosis
Encouraging data were presented for FGF19-positive tumours and those with worse hepatic function, performance status or advanced vascular invasion
Givastomig combined with immunochemotherapy shows clinical activity in metastatic gastro-oesophageal adenocarcinomas
Preliminary results revealed that the combination of claudin 18.2/4-1BB bispecific antibody with nivolumab and mFOLFOX was also well tolerated
Embracing interdisciplinary collaboration for an AI-driven oncology
ESMO now welcomes members from other disciplines to support and expedite the digital transformation of cancer care
AI-driven tool shows to improve risk stratification in colorectal cancer
A system integrating computer tomography scans and pathological markers offers promise to personalise adjuvant therapy
Advancing perioperative treatment in resectable non-small cell lung cancer
Findings from the NeoADAURA and the CheckMate 816 provide novel insights on the role of neoadjuvant osimertinib and nivolumab in the perioperative setting